• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Stimulating severe COVID-19: the potential role of GM-CSF antagonism.

作者信息

Leavis Helen L, van de Veerdonk Frank L, Murthy Srinivas

机构信息

Department of Rheumatology and Clinical Immunology, Utrecht University, University Medical Center Utrecht, Netherlands.

Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.

出版信息

Lancet Respir Med. 2022 Mar;10(3):223-224. doi: 10.1016/S2213-2600(21)00539-7. Epub 2021 Dec 1.

DOI:10.1016/S2213-2600(21)00539-7
PMID:34863335
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8635456/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ef/8635456/5271e9e22126/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ef/8635456/5271e9e22126/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ef/8635456/5271e9e22126/fx1_lrg.jpg

相似文献

1
Stimulating severe COVID-19: the potential role of GM-CSF antagonism.刺激重症新型冠状病毒肺炎：粒细胞-巨噬细胞集落刺激因子拮抗作用的潜在作用
Lancet Respir Med. 2022 Mar;10(3):223-224. doi: 10.1016/S2213-2600(21)00539-7. Epub 2021 Dec 1.
2
GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches.GM-CSF 疗法治疗 COVID-19：调和对立的治疗方法。
Nat Rev Immunol. 2020 Aug;20(8):507-514. doi: 10.1038/s41577-020-0357-7. Epub 2020 Jun 23.
3
G-CSF and GM-CSF Are Different. Which One Is Better for COVID-19?粒细胞集落刺激因子和粒细胞-巨噬细胞集落刺激因子有所不同。哪一种对新冠病毒病更有效？
Acta Haematol. 2021;144(4):355-359. doi: 10.1159/000510352. Epub 2020 Aug 13.
4
Is G-CSF Dangerous in COVID-19: Why Not Use GM-CSF?粒细胞集落刺激因子在新冠病毒肺炎中是否危险：为何不使用粒-巨噬细胞集落刺激因子？
Acta Haematol. 2021;144(3):350-351. doi: 10.1159/000512574. Epub 2020 Nov 6.
5
Chronic pharmacological antagonism of the GM-CSF receptor in mice does not replicate the pulmonary alveolar proteinosis phenotype but does alter lung surfactant turnover.在小鼠中慢性药理学拮抗 GM-CSF 受体不会复制肺表面活性物质蛋白沉积症表型，但会改变肺表面活性剂的转化。
Clin Sci (Lond). 2021 Nov 26;135(22):2559-2573. doi: 10.1042/CS20210713.
6
Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis.粒细胞集落刺激因子（G-CSF）和粒细胞-巨噬细胞集落刺激因子（GM-CSF）治疗脓毒症：一项荟萃分析。
Crit Care. 2011;15(1):R58. doi: 10.1186/cc10031. Epub 2011 Feb 10.
7
Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.单独使用连续输注粒细胞巨噬细胞集落刺激因子或随后使用粒细胞集落刺激因子，以增强高剂量化疗和自体骨髓移植治疗淋巴系统恶性肿瘤后的植入。
Bone Marrow Transplant. 1996 Jun;17(6):951-6.
8
Granulocyte macrophage colony-stimulating factor has come of age: From a vaccine adjuvant to antiviral immunotherapy.粒细胞巨噬细胞集落刺激因子已经成熟：从疫苗佐剂到抗病毒免疫疗法。
Cytokine Growth Factor Rev. 2021 Jun;59:101-110. doi: 10.1016/j.cytogfr.2021.01.001. Epub 2021 Jan 9.
9
Granulocyte-macrophage colony-stimulating factor: an immunotarget for sepsis and COVID-19.粒细胞-巨噬细胞集落刺激因子：脓毒症和新型冠状病毒肺炎的一个免疫靶点
Cell Mol Immunol. 2021 Aug;18(8):2057-2058. doi: 10.1038/s41423-021-00719-3. Epub 2021 Jul 19.
10
[Low-dose granulocyte colony-stimulating factor combined with granulocyte-macrophage colony-stimulating factor for mobilizing peripheral CD34+ hematopoietic progenitor cells].低剂量粒细胞集落刺激因子联合粒细胞-巨噬细胞集落刺激因子用于动员外周血CD34+造血祖细胞
Di Yi Jun Yi Da Xue Xue Bao. 2004 Sep;24(9):1051-2.

引用本文的文献

1
Viral mitochondriopathy in COVID-19.新冠病毒感染中的病毒性线粒体病
Redox Biol. 2025 Jul 12;85:103766. doi: 10.1016/j.redox.2025.103766.
2
Aged garlic extract major constituent S-1-propenyl-l-cysteine inhibits proinflammatory mRNA expression in bronchial epithelial IB3-1 cells exposed to the BNT162b2 vaccine.aged大蒜提取物的主要成分S-1-丙烯基-L-半胱氨酸可抑制暴露于BNT162b2疫苗的支气管上皮IB3-1细胞中的促炎mRNA表达。
Exp Ther Med. 2025 Jun 10;30(2):153. doi: 10.3892/etm.2025.12903. eCollection 2025 Aug.
3
The association of maternal COVID-19-infection during pregnancy on the neonatal immune profile and associations with later diagnosis of neurodevelopmental disorders.

本文引用的文献

1
A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR).一项抗 GM-CSF 单克隆抗体奥替利珠单抗治疗重症 COVID-19 肺炎的随机临床试验（OSCAR）。
Eur Respir J. 2023 Feb 2;61(2). doi: 10.1183/13993003.01870-2021. Print 2023 Feb.
2
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.伦齐单抗治疗 COVID-19 肺炎住院患者（LIVE-AIR）：一项 3 期、随机、安慰剂对照试验。
Lancet Respir Med. 2022 Mar;10(3):237-246. doi: 10.1016/S2213-2600(21)00494-X. Epub 2021 Dec 1.
3
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
孕期母亲感染新冠病毒与新生儿免疫特征的关联以及与神经发育障碍后期诊断的关联。
Brain Behav Immun. 2025 Jan;123:1071-1080. doi: 10.1016/j.bbi.2024.11.014. Epub 2024 Nov 10.
4
Divergent autoantibody and cytokine levels in COVID-19 sepsis patients influence survival.COVID-19 脓毒症患者中不同的自身抗体和细胞因子水平影响生存。
J Med Virol. 2024 Oct;96(10):e29935. doi: 10.1002/jmv.29935.
5
Immune signature in vaccinated versus non-vaccinated aged people with COVID-19 pneumonia.接种疫苗和未接种疫苗的老年 COVID-19 肺炎患者的免疫特征。
J Transl Med. 2024 Aug 12;22(1):755. doi: 10.1186/s12967-024-05556-2.
6
COVID-19 Pneumonia and Cytokine Storm Syndrome.新型冠状病毒肺炎及细胞因子风暴综合征
Adv Exp Med Biol. 2024;1448:307-319. doi: 10.1007/978-3-031-59815-9_22.
7
Autoimmune Pulmonary Alveolar Proteinosis That Improved after a COVID-19 Episode.自身免疫性肺泡蛋白沉积症在 COVID-19 发作后改善。
Intern Med. 2023 Aug 1;62(15):2237-2241. doi: 10.2169/internalmedicine.1592-23. Epub 2023 May 10.
8
Hemophagocytic Syndrome and COVID-19: A Comprehensive Review.噬血细胞综合征与新型冠状病毒肺炎：综述
Cureus. 2023 Mar 14;15(3):e36140. doi: 10.7759/cureus.36140. eCollection 2023 Mar.
9
The natural killer cell-associated rs9916629-C allele is a novel genetic risk factor for fatal COVID-19.自然杀伤细胞相关的 rs9916629-C 等位基因是导致 COVID-19 患者死亡的新的遗传风险因素。
J Med Virol. 2023 Jan;95(1):e28404. doi: 10.1002/jmv.28404.
10
Efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in COVID-19 patients: a meta-analysis.GM-CSF 抗体在 COVID-19 患者中的疗效和安全性：一项荟萃分析。
Inflammopharmacology. 2023 Feb;31(1):275-285. doi: 10.1007/s10787-022-01105-9. Epub 2022 Nov 29.
托珠单抗治疗 COVID-19 住院患者的疗效（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
4
Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial.重度新冠肺炎肺炎和全身炎症反应患者使用马夫瑞单抗（MASH-COVID）：一项研究者发起的多中心、双盲、随机、安慰剂对照试验。
Lancet Rheumatol. 2021 Jun;3(6):e410-e418. doi: 10.1016/S2665-9913(21)00070-9. Epub 2021 Mar 17.
5
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.COVID-19 重症患者的白细胞介素 6 受体拮抗剂。
N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25.
6
GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches.GM-CSF 疗法治疗 COVID-19：调和对立的治疗方法。
Nat Rev Immunol. 2020 Aug;20(8):507-514. doi: 10.1038/s41577-020-0357-7. Epub 2020 Jun 23.
7
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
8
The immunopathology of sepsis and potential therapeutic targets.脓毒症的免疫病理学及潜在治疗靶点
Nat Rev Immunol. 2017 Jul;17(7):407-420. doi: 10.1038/nri.2017.36. Epub 2017 Apr 24.
9
Pivotal roles of GM-CSF in autoimmunity and inflammation.粒细胞-巨噬细胞集落刺激因子在自身免疫和炎症中的关键作用。
Mediators Inflamm. 2015;2015:568543. doi: 10.1155/2015/568543. Epub 2015 Mar 8.
10
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know.粒细胞-巨噬细胞集落刺激因子（GM-CSF）与T细胞反应：我们所知道和不知道的
Cell Res. 2006 Feb;16(2):126-33. doi: 10.1038/sj.cr.7310017.